ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1753

Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model

Christopher Ritchlin1, Javier Rangel-Moreno2, Angel Rangel-Garcia3, Marissa Krantz4, Madison Brien2, Thiloginy Sathilaseenlan2, Jeffrey Fox5, Ronald Wood2 and Maria de la Luz Garcia-Hernandez3, 1University of Rochester Medical Center, Canandaigua, NY, 2University of Rochester, Rochester, NY, 3University of Rochester, West Henrietta, NY, 4University of Rochester, Bethesda, MD, 5University od Rochester, Rochester, NY

Meeting: ACR Convergence 2025

Keywords: Animal Model, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

Session Type: Abstract Session

Session Time: 10:15AM-10:30AM

Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic axial inflammation (AxPsA) are not well understood and longitudinal studies to examine the immune mechanisms involved in disease pathogenesis and progression using human cells in an animal model have not been performed. In previous analyses, we demonstrated that human PsA phenotypes in the peripheral skeleton, entheses and skin are recapitulated in the NSG-GM3 humanized mouse model. Herein, we examined if axial disease is phenocopied in this mouse model.

Methods: Two groups of NSG-SGM3 mice were injected with serum and peripheral blood mononuclear cells (PBMC) collected from three biologic naive PsA patients with inflammatory back pain and radiographic or MRI documented sacroiliitis (AxPsA) and controls (PsA patients without axial disease). At day 30, mice were anesthetized, and their spines were dissected for radiographic and micro-CT scan analysis. Tissue sections from decalcified spines were stained with anti CD45, CD14, CD8, Ki67, TNF and Il-17 antibodies.

Results: NSG-SGM3 mice injected with serum and engrafted with PBMC from patients with AxPsA exhibited pronounced spinal deformities. Radiographic imaging revealed marked cervical and thoracic kyphosis, bone erosion and osteoproliferation in the tail and micro-computed tomography (micro-CT) scans identified both bone resorption and pathological bone fusion in the sacroiliac joint and lumbar spine. In contrast, mice injected with PBMC and sera from non-AxPsA controls did not demonstrate significant inflammation or structural alterations. Histological analysis in the spine of mice injected with AxSpA PBMC and sera revealed accumulation of lymphocytes in and around the dorsal root ganglion (DRG) and in the surrounding muscle. Inflammatory cell infiltrates were characterized by proliferating CD3 T and CD8 T cells that expressed both TNF and IL-17. TNF and IL-17 expression were elevated most notably in the DRG.

Conclusion: Injection of PBMC and sera from AxPsA patients recapitulated axial clinical features in hu PsA mice. HuAxPsA mice developed kyphosis in the distal cervical and thoracic spine and structural damage in the lower lumbar and sacroiliac region and tail, including bone loss and new bone formation. Proliferating CD3+ T and CD8+ T cells expressing TNF and IL-17 were noted near the DRG and in surrounding tissues and paravertebral muscles. This model will accelerate investigation of immune mechanisms in AxPsA.

Supporting image 1Figure 1. Humanized NSG-SGM3 mice generated with sera and PBMC from AxPsA and non-AxPA patients. 1) Hu-AxPsA mice demonstrated (a), cervical and thoracic kyphosis not seen in controls (b) (c), spinal fusion and erosion in the lumbar spine (c, * fusion and erosion below), (d) tail inflammation and necrosis and (e) L5, S1 fusion * and bone resorption ** not observed in controls (f). Figure 2. Alcian blue staining of the spine shows abundant infiltrating immune cells (dotted red line) around the dorsal root ganglion (DRG) (a,c) and low infiltration in the spine of hu-non-AxPsA mice (b,d). Immunofluorescence staining shows more proliferating CD3 (red and white) and IL-17+ (red) TNF + (green) CD8+ (white) and Il-17+ TNF+ cells in the DRG of hu-AxPsA (e, g) compared to hu-non-AxpSA mice (f,h).


Disclosures: C. Ritchlin: AbbVie, 2, Amgen, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, 5, MoonLake Pharma, 2, Novartis, 2, 5, Solara, 2, UCB, 2; J. Rangel-Moreno: None; A. Rangel-Garcia: None; M. Krantz: None; M. Brien: None; T. Sathilaseenlan: None; J. Fox: None; R. Wood: None; M. Garcia-Hernandez: None.

To cite this abstract in AMA style:

Ritchlin C, Rangel-Moreno J, Rangel-Garcia A, Krantz M, Brien M, Sathilaseenlan T, Fox J, Wood R, Garcia-Hernandez M. Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/axial-psoriatic-arthritis-is-phenocopied-in-a-humanized-mouse-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/axial-psoriatic-arthritis-is-phenocopied-in-a-humanized-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology